FDA Approves Nourianz for Parkinson Disease

On August 27, 2019, the Food and Drug Administration (FDA) approved a new drug application (NDA) for Nourianz (istradefylline; Kyowa Kirin Inc.), an oral selective adenosine A2A receptor antagonist for use as an add-on treatment to levodopa/carbidopa in adult patients...